Breakpoint Therapeutics is a company that discover and develop new anti-cancer drugs.
Breakpoint Therapeutics is a company that discover and develop new anti-cancer drugs. By targeting the DNA damage response (“DDR”) in cancer cells, Breakpoint Therapeutics aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. Their mission is to develop drugs that succeed and complement PARP inhibitors and facilitate the cure of therapy resistant cancers.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 9, 2019 | Series Unknown | €30M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Evotec | — | Series Unknown |